Yossi S, Nguyen D, Khodri M, Reure J, Cervellera M, Lamberth F, Marchand V, Mammar V, Renoult F, Louet E, Coquard R, Barbet N, Lorchel F
Centre de radiothérapie Charcot, ORLAM, Sainte Foy Lès Lyon, France; Centre de radiothérapie Mermoz, ORLAM, Lyon, France; Centre de radiothérapie et Oncologie, ORLAM, Macon, France; Centre de radiothérapie Bayard, ORLAM, Villeurbanne, France.
Centre de radiothérapie Charcot, ORLAM, Sainte Foy Lès Lyon, France; Centre de radiothérapie Mermoz, ORLAM, Lyon, France; Centre de radiothérapie et Oncologie, ORLAM, Macon, France; Centre de radiothérapie Bayard, ORLAM, Villeurbanne, France.
Cancer Radiother. 2020 Apr;24(2):159-165. doi: 10.1016/j.canrad.2019.10.006. Epub 2020 Mar 6.
Ovarian cancer is the fifth most common cancer in women in France with 4714 new cases in 2017. More than 70% of patients whose disease is initially locally advanced will present locoregional or distant recurrence. Therapeutic options in this situation are not consensual. They are based on chemotherapy possibly associated with an iterative cytoreductive surgery when it is bearable by the patient. The place of radiotherapy in the management of the disease is hidden in the vast majority of national or international standards. We conducted a general review of the literature to clarify the role of irradiation in the global management of ovarian cancers, particularly in recurrence.
卵巢癌是法国女性中第五大常见癌症，2017年有4714例新发病例。超过70%疾病最初为局部晚期的患者会出现局部区域或远处复发。这种情况下的治疗方案尚无共识。治疗方案基于化疗，若患者能够耐受，可能会联合反复的减瘤手术。在绝大多数国家或国际标准中，放疗在该疾病治疗中的地位并不明确。我们对文献进行了全面综述，以阐明放疗在卵巢癌整体治疗中的作用，尤其是在复发治疗中的作用。
